BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18559414)

  • 1. Reformulating the hazard ratio to enhance communication with clinical investigators.
    Moser BK; McCann MH
    Clin Trials; 2008; 5(3):248-52. PubMed ID: 18559414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of cumulative incidence function under the proportional hazards model.
    Cheng SC; Fine JP; Wei LJ
    Biometrics; 1998 Mar; 54(1):219-28. PubMed ID: 9544517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple test for independent censoring under the proportional hazards model.
    Lee SY; Wolfe RA
    Biometrics; 1998 Sep; 54(3):1176-82. PubMed ID: 9840972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trials.
    Keene ON
    Stat Med; 2002 Dec; 21(23):3687-700. PubMed ID: 12436464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generating survival times to simulate Cox proportional hazards models.
    Bender R; Augustin T; Blettner M
    Stat Med; 2005 Jun; 24(11):1713-23. PubMed ID: 15724232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bootstrap analysis of multivariate failure time data.
    Monaco J; Cai J; Grizzle J
    Stat Med; 2005 Nov; 24(22):3387-400. PubMed ID: 16237657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-parametric procedure for evaluating treatment effect in the meta-analysis of survival data.
    Moodie PF; Nelson NA; Koch GG
    Stat Med; 2004 Apr; 23(7):1075-93. PubMed ID: 15057879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple approach to power and sample size calculations in logistic regression and Cox regression models.
    Vaeth M; Skovlund E
    Stat Med; 2004 Jun; 23(11):1781-92. PubMed ID: 15160408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of the proportional hazard in two-treatment-group clinical trials.
    Bernstein L; Anderson J; Pike MC
    Biometrics; 1981 Sep; 37(3):513-9. PubMed ID: 7317558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The estimation of average hazard ratios by weighted Cox regression.
    Schemper M; Wakounig S; Heinze G
    Stat Med; 2009 Aug; 28(19):2473-89. PubMed ID: 19472308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some diagnostic methods for Cox regression models through hazard smoothing.
    Gray RJ
    Biometrics; 1990 Mar; 46(1):93-102. PubMed ID: 2190638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing interactions of binary time-dependent covariates with time in cox proportional hazards regression models using cubic spline functions.
    Heinzl H; Kaider A; Zlabinger G
    Stat Med; 1996 Dec; 15(23):2589-601. PubMed ID: 8961465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.
    Cai T; Gilbert PB; Self SG
    J Biopharm Stat; 2006; 16(4):517-38. PubMed ID: 16892911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.
    Royston P; Parmar MK
    Stat Med; 2002 Aug; 21(15):2175-97. PubMed ID: 12210632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A ratio test in active control non-inferiority trials with a time-to-event endpoint.
    Wang YC; Chen G; Chi GY
    J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-rank hazard regression for modelling non-proportional hazards.
    Perperoglou A; le Cessie S; van Houwelingen HC
    Stat Med; 2006 Aug; 25(16):2831-45. PubMed ID: 16158396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes.
    Austin PC
    J Clin Epidemiol; 2010 Jan; 63(1):46-55. PubMed ID: 19595575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating surrogate markers of clinical outcome when measured with error.
    Dafni UG; Tsiatis AA
    Biometrics; 1998 Dec; 54(4):1445-62. PubMed ID: 9883544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing two crossing hazard rates by Cox proportional hazards modelling.
    Liu K; Qiu P; Sheng J
    Stat Med; 2007 Jan; 26(2):375-91. PubMed ID: 16538703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.